Merck & Co., Inc. Confirms Major Acquisition

In a significant development in the biopharmaceutical industry, Merck & Co., Inc. announced on Wednesday its decision to acquire Verona Pharma, a UK-based biopharmaceutical company, for a staggering $10 billion. This strategic move is set to enhance Merck's portfolio with Verona's innovative treatments, including Ohtuvayre for chronic obstructive pulmonary disease (COPD).

Details of the Deal

The agreement stipulates that Merck will pay $107 per American Depository Share (ADS) of Verona Pharma. Following initial reports of a potential takeover, both companies have now reached a definitive agreement, with the transaction expected to close in the fourth quarter of 2025.

Leadership's Perspective

"This acquisition underscores our dedication to bringing groundbreaking treatments to patients and exemplifies our commitment to a science-led, value-driven business development strategy," stated Rob Davis, Chief Executive of Merck.